Vectura Group (LON:VEC)‘s stock had its “buy” rating restated by equities researchers at Numis Securities in a note issued to investors on Wednesday, Digital Look reports. They currently have a GBX 160 ($2.09) target price on the stock. Numis Securities’ target price would suggest a potential upside of 102.84% from the stock’s current price.
Several other analysts also recently commented on the stock. Shore Capital reissued a “hold” rating on shares of Vectura Group in a research report on Wednesday. Peel Hunt reaffirmed a “hold” rating on shares of Vectura Group in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an “overweight” rating for the company in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Vectura Group has a consensus rating of “Buy” and a consensus target price of GBX 116.67 ($1.52).
VEC stock opened at GBX 78.88 ($1.03) on Wednesday. The company has a quick ratio of 1.90, a current ratio of 2.35 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $519.81 million and a price-to-earnings ratio of -5.98. Vectura Group has a 12 month low of GBX 65.85 ($0.86) and a 12 month high of GBX 90.15 ($1.18).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Further Reading: Trading signals using Bollinger bands
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.